Total Payments
$178,683
2024 Payments
$35,867
Companies
35
Transactions
363
Medicare Patients
1,766
Medicare Billing
$198,132
Payment Breakdown by Category
Other$135,584 (75.9%)
Consulting$17,916 (10.0%)
Travel$16,569 (9.3%)
Food & Beverage$8,608 (4.8%)
Education$6.61 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $62,659 | 35 | 35.1% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $36,000 | 13 | 20.1% |
| Honoraria | $24,100 | 11 | 13.5% |
| Consulting Fee | $17,916 | 4 | 10.0% |
| Travel and Lodging | $16,569 | 56 | 9.3% |
| Compensation for serving as faculty or as a speaker for a medical education program | $12,825 | 7 | 7.2% |
| Food and Beverage | $8,608 | 236 | 4.8% |
| Education | $6.61 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $40,288 | 80 | $0 (2024) |
| GENZYME CORPORATION | $36,594 | 22 | $0 (2024) |
| Horizon Pharma plc | $29,710 | 37 | $0 (2018) |
| Valeant Pharmaceuticals North America LLC | $22,199 | 30 | $0 (2017) |
| Allergan Inc. | $18,582 | 74 | $0 (2019) |
| ABBVIE INC. | $15,274 | 48 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $5,683 | 9 | $0 (2024) |
| Janssen Biotech, Inc. | $4,664 | 15 | $0 (2024) |
| Eli Lilly and Company | $2,188 | 1 | $0 (2023) |
| Horizon Therapeutics plc | $800.00 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $35,867 | 64 | GENZYME CORPORATION ($24,447) |
| 2023 | $30,511 | 41 | GENZYME CORPORATION ($12,147) |
| 2022 | $10,031 | 20 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($5,978) |
| 2021 | $8,805 | 44 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($5,823) |
| 2020 | $1,006 | 7 | AbbVie Inc. ($929.95) |
| 2019 | $8,673 | 31 | Allergan Inc. ($4,351) |
| 2018 | $37,216 | 75 | Horizon Pharma plc ($17,456) |
| 2017 | $46,574 | 81 | Valeant Pharmaceuticals North America LLC ($22,199) |
All Payment Transactions
363 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $7.02 | General |
| Category: Immunology | ||||||
| 12/10/2024 | AIMMUNE THERAPEUTICS, INC. | VOWST (Biological) | Food and Beverage | In-kind items and services | $27.30 | General |
| Category: GI | ||||||
| 12/05/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $21.89 | General |
| Category: Diabetes | ||||||
| 11/21/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $17.14 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/19/2024 | ABBVIE INC. | LINZESS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,425.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/13/2024 | Janssen Biotech, Inc. | STELARA (Biological), TREMFYA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $521.00 | General |
| Category: Immunology | ||||||
| 11/05/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $10.36 | General |
| Category: IMMUNOLOGY | ||||||
| 10/30/2024 | Janssen Biotech, Inc. | STELARA (Biological), TREMFYA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $695.00 | General |
| Category: Immunology | ||||||
| 10/27/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $55.64 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/27/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $40.50 | General |
| Category: Immunology | ||||||
| 10/26/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,128.00 | General |
| Category: Immunology | ||||||
| 10/23/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,839.00 | General |
| Category: Immunology | ||||||
| 10/23/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $124.97 | General |
| Category: Immunology | ||||||
| 10/22/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Food and Beverage | In-kind items and services | $129.71 | General |
| Category: Immunology | ||||||
| 10/22/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $8.39 | General |
| Category: IMMUNOLOGY | ||||||
| 10/17/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $30.64 | General |
| Category: Immunology | ||||||
| 10/10/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $16.33 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 10/02/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,352.00 | General |
| Category: Immunology | ||||||
| 10/02/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $71.88 | General |
| Category: Immunology | ||||||
| 10/01/2024 | IRONWOOD PHARMACEUTICALS, INC | Linzess (Drug) | Food and Beverage | Cash or cash equivalent | $14.90 | General |
| Category: GI | ||||||
| 09/25/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | Cash or cash equivalent | $44.17 | General |
| Category: Immunology | ||||||
| 09/25/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Travel and Lodging | Cash or cash equivalent | $30.00 | General |
| Category: Immunology | ||||||
| 09/18/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $18.27 | General |
| Category: Gastroenterology | ||||||
| 09/12/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $19.69 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/10/2024 | ABBVIE INC. | CREON (Drug), LINZESS | Food and Beverage | In-kind items and services | $7.18 | General |
| Category: ENDOCRINOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 463 | 488 | $197,412 | $53,524 |
| 2022 | 8 | 436 | 462 | $189,947 | $47,952 |
| 2021 | 10 | 502 | 556 | $198,729 | $58,682 |
| 2020 | 9 | 365 | 401 | $127,816 | $37,974 |
Total Patients
1,766
Total Services
1,907
Medicare Billing
$198,132
Procedure Codes
36
All Medicare Procedures & Services
36 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 71 | 76 | $48,680 | $13,674 | 28.1% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 107 | 108 | $56,356 | $10,975 | 19.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 79 | 79 | $20,756 | $8,079 | 38.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 72 | 89 | $18,867 | $8,031 | 42.6% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 87 | 88 | $31,420 | $6,500 | 20.7% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 16 | 16 | $6,747 | $2,782 | 41.2% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 20 | 20 | $9,300 | $2,000 | 21.5% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 11 | 12 | $5,286 | $1,481 | 28.0% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 60 | 63 | $41,517 | $11,980 | 28.9% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 110 | 111 | $61,494 | $11,576 | 18.8% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 84 | 85 | $31,195 | $6,649 | 21.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 81 | 101 | $24,947 | $6,280 | 25.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 46 | 46 | $10,270 | $4,397 | 42.8% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2022 | 13 | 14 | $6,510 | $2,294 | 35.2% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 12 | 12 | $5,580 | $2,110 | 37.8% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 16 | 16 | $4,976 | $1,354 | 27.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 14 | 14 | $3,458 | $1,313 | 38.0% |
| 45385 | Removal of polyps or growths in large bowel using an endoscope (colonoscopy) using a mechanical snare | Facility | 2021 | 60 | 65 | $42,835 | $12,539 | 29.3% |
| 45380 | Biopsy of the large bowel using an endoscope (colonoscopy) | Facility | 2021 | 92 | 93 | $51,522 | $10,931 | 21.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 101 | 147 | $25,814 | $10,361 | 40.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 98 | 98 | $22,692 | $9,738 | 42.9% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 75 | 76 | $27,892 | $5,782 | 20.7% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2021 | 21 | 21 | $9,765 | $3,437 | 35.2% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2021 | 11 | 11 | $5,115 | $1,987 | 38.8% |
| 45378 | Diagnostic examination of the colon (large bowel) using an endoscope(colonoscopy); high risk | Facility | 2021 | 13 | 13 | $6,045 | $1,590 | 26.3% |
About Pooja Singhal
Pooja Singhal is a Gastroenterology healthcare provider based in Oklahoma City, Oklahoma. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/24/2008. The National Provider Identifier (NPI) number assigned to this provider is 1588825368.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Pooja Singhal has received a total of $178,683 in payments from pharmaceutical and medical device companies, with $35,867 received in 2024. These payments were reported across 363 transactions from 35 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($62,659).
As a Medicare-enrolled provider, Singhal has provided services to 1,766 Medicare beneficiaries, totaling 1,907 services with total Medicare billing of $198,132. Data is available for 4 years (2020–2023), covering 36 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Oklahoma City, OK
- Active Since 06/24/2008
- Last Updated 10/26/2015
- Taxonomy Code 207RG0100X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1588825368
Products in Payments
- DUPIXENT (Biological) $42,277
- XIFAXAN (Drug) $41,245
- LINZESS (Drug) $30,637
- PRIMARY CARE - DISEASE STATE (Drug) $29,710
- TRULANCE (Drug) $12,597
- RELISTOR (Drug) $6,509
- TREMFYA (Drug) $3,295
- VIBERZI (Drug) $2,967
- PLENVU (Drug) $2,099
- STELARA (Biological) $1,620
- KRYSTEXXA (Biological) $800.00
- Barrx (Device) $700.00
- OverStitch Endoscopic Suturing System (Device) $690.23
- LINX Reflux Management System (Device) $189.55
- LINX (Device) $154.06
- VOQUEZNA (Drug) $143.18
- OCALIVA (Drug) $98.10
- CREON (Drug) $56.09
- RINVOQ (Biological) $52.24
- HUMIRA (Biological) $45.60
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Oklahoma City
George Salem, Md, MD
Gastroenterology — Payments: $872,730
Gastroenterology $872,730
Tauseef Ali, M.d, M.D
Gastroenterology — Payments: $616,367
Gastroenterology $616,367
Matthew Mcbride, Md, MD
Gastroenterology — Payments: $83,407
Gastroenterology $83,407
Dr. Trushar Patel, M.d, M.D
Gastroenterology — Payments: $81,054
Gastroenterology $81,054
Dr. David Stokesberry, M.d, M.D
Gastroenterology — Payments: $41,079
Gastroenterology $41,079
Sanjay Sikka, M.d, M.D
Gastroenterology — Payments: $31,487
Gastroenterology $31,487